TT-034: Phase I/IIa started

Benitec began an open-label, U.S. Phase I/IIa trial to evaluate single ascending-doses of IV TT-034 in up to 5 cohorts in 14 patients with chronic HCV genotype 1 infection. Benitec gained TT-034 throu...